Rate My Professor Reyhaneh Farghadani

Reyhaneh Farghadani serves as a Lecturer in the Jeffrey Cheah School of Medicine and Health Sciences at Monash University Malaysia, where she contributes to the Biomedical Science academic staff. She earned her Doctor of Philosophy in Molecular Medicine from the University of Malaya from 2015 to 2021. Previously, she completed a Master of Science in Biotechnology at Universiti Teknologi Malaysia from 2011 to 2013, and a Bachelor of Science in Cellular and Molecular Biology-Genetics from Shahrekord University from 2005 to 2009. After completing her PhD, Farghadani joined Monash University Malaysia as a postdoctoral researcher in 2019, progressing to her current position as Lecturer.

Farghadani's research centers on cancer biology, with a focus on the promising role of natural compounds in cancer therapy, particularly breast cancer and triple-negative breast cancer. Her investigations cover receptor tyrosine kinases and their signaling pathways, apoptosis as a double-edged sword in cancer, ROS-mediated apoptosis, modulation of long non-coding RNAs, flavonoids as inhibitors, and reprogramming the breast tumor immune microenvironment for enhanced immunotherapy. Key publications include "Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer" (2021), "Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer" (2022), "Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer" (2021), "The Anticancer Mechanism of Action of Selected Polyphenols in Triple-Negative Breast Cancer (TNBC)" (2023), "Flavonoids as Receptor Tyrosine Kinase Inhibitors in Lung Cancer" (2023), "Natural Quinones Induce ROS-Mediated Apoptosis and Inhibit Cell Migration in PANC-1 Human Pancreatic Cancer Cell Line" (2022), "Novel Indole Schiff Base β-Diiminato Compound as an Anti-Cancer Agent Against Triple-Negative Breast Cancer" (2024), and "Reprogramming the Breast Tumor Immune Microenvironment: Cold-to-Hot Transition for Enhanced Immunotherapy" (2025). These works highlight her contributions to advancing natural product-based strategies in cancer drug discovery and therapy.